QTTB vs. ACRS, CMRX, LFVN, VACC, BRNS, YS, ONCY, SPRO, MIST, and CNTB
Should you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Aclaris Therapeutics (ACRS), Chimerix (CMRX), LifeVantage (LFVN), Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), YS Biopharma (YS), Oncolytics Biotech (ONCY), Spero Therapeutics (SPRO), Milestone Pharmaceuticals (MIST), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 16.1% of Q32 Bio shares are held by company insiders. Comparatively, 5.5% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Q32 Bio has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -248.28%. Aclaris Therapeutics' return on equity of -61.03% beat Q32 Bio's return on equity.
Aclaris Therapeutics received 375 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 66.96% of users gave Aclaris Therapeutics an outperform vote.
Q32 Bio has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
Q32 Bio presently has a consensus price target of $47.50, indicating a potential upside of 75.08%. Aclaris Therapeutics has a consensus price target of $22.25, indicating a potential upside of 1,801.71%. Given Aclaris Therapeutics' higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Q32 Bio.
Aclaris Therapeutics has higher revenue and earnings than Q32 Bio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aclaris Therapeutics had 15 more articles in the media than Q32 Bio. MarketBeat recorded 20 mentions for Aclaris Therapeutics and 5 mentions for Q32 Bio. Aclaris Therapeutics' average media sentiment score of 0.80 beat Q32 Bio's score of -0.34 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Summary
Aclaris Therapeutics beats Q32 Bio on 11 of the 18 factors compared between the two stocks.
Get Q32 Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
